Medical/Pharmaceuticals
WuXi Biologics Hosts Third CRDMO Day in Japan, Accelerating Biopharma Innovation from IND to Commercialization
TOKYO, May 20, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), recently hosted its third CRDMO Day in Tokyo, bringing together senior leaders and experts from Japan's biopharmaceutical industry, exchanging the ...
2026-05-20 13:44
4358
Haier Biomedical Publishes 2025 Sustainability Report: Committed to Building a Platform for Technology, Industry and Social Responsibility
QINGDAO, China, May 20, 2026 /PRNewswire/ -- Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, has released its 2025 Sustainability Report, providing a comprehensive overview of the company's measurable progress achieved in environmental, social, and governance...
2026-05-20 12:23
4616
Agilent and Singapore's NATi Partner to Advance Lipid-Conjugated Oligonucleotide Research
Collaboration expands research of new delivery platform beyond liver tissues
supporting potential preclinical development and strengthens Singapore's
position as a biomedical innovation hub
SINGAPORE, May 20, 2026 /PRNewswire/ -- Agilent Technologies Inc.
2026-05-20 11:00
3958
ATxSummit 2026 Opens with Shared Regional Ambition to Harness AI for Public Good
SINGAPORE, May 20, 2026 /PRNewswire/ -- ATxSummit 2026, hosted by the Infocomm Media Development Authority of Singapore, officially kicked off this evening with Singapore President Tharman Shanmugaratnam as the Guest-of-Honour at the Opening Gala Dinner at Gardens by the Bay. This year's ATxSummi...
2026-05-20 08:43
4730
Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline
SHANGHAI and HONG KONG, May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-05-20 08:00
4854
PRC-Saltillo Named to Forbes Accessibility 200 List
WOOSTER, Ohio, May 20, 2026 /PRNewswire/ -- PRC-Saltillo has been named to the
2026 Forbes Accessibility 200 list
2026-05-20 01:38
4181
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery
Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening HOUSTON, May 19, 2026 /PRNewswire/ -- Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, is proud to announce the launch of its innovative XPressMAX™ Cell-Free ...
2026-05-19 23:45
6334
PartnerOne Launches a Global Philanthropic Initiative to Expand Pediatric Surgical Care in Developing Countries
PartnerOne Global Surgery (POGS) begins with a $10 million commitment from PartnerOne and an inaugural partnership with Montreal Children's Hospital, one of the most renowned pediatric hospitals in the world. RIVERSIDE, Calif., May 19, 2026 /PRNewswire/ -- PartnerOne announced the launch of Part...
2026-05-19 21:00
3902
ALR TECHNOLOGIES HAS LAUNCHED THE GLUCURVE PET CGM IN CANADA
SINGAPORE, May 19, 2026 /PRNewswire/ -- ALR Technologies SG Ltd. ("ALRT" or the
"Company") (OTC: ALRTF), the diabetes management company, announces the
GluCurve Pet CGM ("GluCurve") is now for sale in Canada at www.GluCurve.ca
2026-05-19 20:28
3551
Fujitsu, SMBC Group and SoftBank agree on alliance to build Japan-made platform for sustainable healthcare
Companies aim to extend healthy life expectancy, optimize management of healthcare institutions, and curb national healthcare costs Sumitomo Mitsui Financial Group, Inc. Fujitsu Limited SoftBank Corp. TOKYO, May 19, 2026 /PRNewswire/ -- Fujitsu Limited (Fujitsu), Sumitomo Mitsui Financial Group,...
2026-05-19 14:28
4813
BIOTRONIK, Charité, and German Heart Center Foundation Announce Partnership to Advance Digital Cardiology
Strategic Initiative Strengthens Berlin as Europe's Hub of Digital Cardiology BERLIN, May 19, 2026 /PRNewswire/ -- BIOTRONIK, die Charité – Universitätsmedizin Berlin, and the German Heart Center Foundation today announced a research and innovation partnership focused on advancing digital and tr...
2026-05-19 14:00
3405
Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic Effects
CBL-514, when combined separately with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide, demonstrated enhanced weight loss, attenuated post-discontinuation weight regain, and greater reductions in subcutaneous and visceral fat in animal studies. The presentation also ma...
2026-05-19 13:19
5250
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
NANJING, China, May 18, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation (CDE) of Chi...
2026-05-19 09:35
5112
Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
* Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza * Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Accro Bio...
2026-05-19 08:00
3929
Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
SAN FRANCISCO and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2026-05-19 08:00
4761
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
* IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. * Maximum dose reached with no dose-limiting toxicities observed. * TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma. MELBOURNE, Australia ...
2026-05-19 05:00
5134
Lifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing
NORWALK, Conn., May 19, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, today announced that it has led Violet Therapeutics' $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC...
2026-05-19 01:03
3358
Major breakthrough of Sanyou Biopharmaceuticals AI-STAL
SHANGHAI, May 18, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals announced today that its independently developed AI-STAL has undergone a significant upgrade, successfully achieving a qualitative leap from "molecular treasure trove" to "intelligent engine", marking the company's entry into a new ...
2026-05-18 22:00
4843
Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial
- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key biomarkers for at least 8 weeks following a single dose, including pSTAT6...
2026-05-18 21:15
5684
Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
* Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®. * Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axill...
2026-05-18 21:00
3935
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 317 media titles]
2026-06-08 10:16
Visa Partners with OpenAI to Power the Next Generation of AI Commerce
[Picked up by 304 media titles]
2026-06-11 09:30QuettaFlow Technologies Strengthens Global Strategic Alliance with Lead Wealth and Showcases VasEdge at COMPUTEX Taipei 2026
[Picked up by 294 media titles]
2026-06-11 10:00
Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 286 media titles]
2026-06-08 09:00
HKC, ANTGAMER, KOORUI Make Strong Debut at COMPUTEX 2026 with World-First Display Innovations
[Picked up by 279 media titles]
2026-06-10 11:13
Most Read
Quantinuum Announces Closing of Upsized Initial Public Offering
2026-06-06 05:08
8128
NYSE Content Update: PointFive Raises $60 Million to Redefine Efficiency
2026-06-08 20:55
7157
SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver
2026-06-06 03:15
6631
